Wu Y, Ding Y, Shen C
Vaccines (Basel). 2022; 10(2).
PMID: 35214714
PMC: 8878595.
DOI: 10.3390/vaccines10020257.
Li Y, Yin S, Issa R, Tong X, Wang G, Xia J
J Clin Transl Hepatol. 2021; 9(4):592-597.
PMID: 34447690
PMC: 8369012.
DOI: 10.14218/JCTH.2021.00051.
Bian Y, Zhang Z, Sun Z, Zhao J, Zhu D, Wang Y
Hepatology. 2017; 66(4):1067-1082.
PMID: 28445927
PMC: 5605403.
DOI: 10.1002/hep.29239.
van Montfoort N, van der Aa E, Woltman A
Front Immunol. 2014; 5:182.
PMID: 24795724
PMC: 4005948.
DOI: 10.3389/fimmu.2014.00182.
Rehermann B
Nat Med. 2013; 19(7):859-68.
PMID: 23836236
PMC: 4482132.
DOI: 10.1038/nm.3251.
Removing N-terminal sequences in pre-S1 domain enhanced antibody and B-cell responses by an HBV large surface antigen DNA vaccine.
Ge G, Wang S, Han Y, Zhang C, Lu S, Huang Z
PLoS One. 2012; 7(7):e41573.
PMID: 22844502
PMC: 3402421.
DOI: 10.1371/journal.pone.0041573.
Construction and immunological evaluation of multivalent hepatitis B virus (HBV) core virus-like particles carrying HBV and HCV epitopes.
Sominskaya I, Skrastina D, Dislers A, Vasiljev D, Mihailova M, Ose V
Clin Vaccine Immunol. 2010; 17(6):1027-33.
PMID: 20410327
PMC: 2884416.
DOI: 10.1128/CVI.00468-09.
PreS1 epitope recognition in newborns after vaccination with the third-generation Sci-B-Vac vaccine and their relation to the antibody response to hepatitis B surface antigen.
Hellstrom U, Madalinski K, Sylvan S
Virol J. 2009; 6:7.
PMID: 19154574
PMC: 2635352.
DOI: 10.1186/1743-422X-6-7.
Bim-mediated deletion of antigen-specific CD8 T cells in patients unable to control HBV infection.
Lopes A, Kellam P, Das A, Dunn C, Kwan A, Turner J
J Clin Invest. 2008; 118(5):1835-45.
PMID: 18398508
PMC: 2289792.
DOI: 10.1172/JCI33402.
Chloroquine enhances human CD8+ T cell responses against soluble antigens in vivo.
Accapezzato D, Visco V, Francavilla V, Molette C, Donato T, Paroli M
J Exp Med. 2005; 202(6):817-28.
PMID: 16157687
PMC: 2212941.
DOI: 10.1084/jem.20051106.
Distribution of hepatitis B viral genotypes and mutations in the core promoter and precore regions in acute forms of liver disease in patients from Chiba, Japan.
Imamura T, Yokosuka O, Kurihara T, Kanda T, Fukai K, Imazeki F
Gut. 2003; 52(11):1630-7.
PMID: 14570734
PMC: 1773865.
DOI: 10.1136/gut.52.11.1630.
Peptide-receptive class I major histocompatibility complex molecules on TAP-deficient and wild-type cells and their roles in the processing of exogenous antigens.
Song R, Porgador A, Harding C
Immunology. 1999; 97(2):316-24.
PMID: 10447748
PMC: 2326830.
DOI: 10.1046/j.1365-2567.1999.00759.x.
Processing of the DRB1*1103-restricted measles virus nucleoprotein determinant 185-199 in the endosomal compartment.
Demotz S, Ammerlaan W, Fournier P, Muller C, Barbey C
Clin Exp Immunol. 1998; 114(2):228-35.
PMID: 9822281
PMC: 1905115.
DOI: 10.1046/j.1365-2249.1998.00716.x.
Efficient class II major histocompatibility complex presentation of endogenously synthesized hepatitis C virus core protein by Epstein-Barr virus-transformed B-lymphoblastoid cell lines to CD4(+) T cells.
Chen M, Shirai M, Liu Z, Arichi T, Takahashi H, Nishioka M
J Virol. 1998; 72(10):8301-8.
PMID: 9733874
PMC: 110194.
DOI: 10.1128/JVI.72.10.8301-8308.1998.
Immune responses throughout hepatitis C virus (HCV) infection: HCV from the immune system point of view.
Abrignani S
Springer Semin Immunopathol. 1997; 19(1):47-55.
PMID: 9266630
DOI: 10.1007/BF00945024.
Class I MHC presentation of exogenous antigens.
Harding C
J Clin Immunol. 1996; 16(2):90-6.
PMID: 8690777
DOI: 10.1007/BF01540955.
Hepatitis B virus immunopathology.
Chisari F, Ferrari C
Springer Semin Immunopathol. 1995; 17(2-3):261-81.
PMID: 8571172
DOI: 10.1007/BF00196169.
Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages.
Kovacsovics-Bankowski M, Clark K, Benacerraf B, Rock K
Proc Natl Acad Sci U S A. 1993; 90(11):4942-6.
PMID: 8506338
PMC: 46629.
DOI: 10.1073/pnas.90.11.4942.
Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles.
Chicz R, Urban R, Gorga J, Vignali D, Lane W, Strominger J
J Exp Med. 1993; 178(1):27-47.
PMID: 8315383
PMC: 2191090.
DOI: 10.1084/jem.178.1.27.
Cytomegalovirus inhibits major histocompatibility class II expression on infected endothelial cells.
Sedmak D, Guglielmo A, Knight D, Birmingham D, Huang E, Waldman W
Am J Pathol. 1994; 144(4):683-92.
PMID: 8160770
PMC: 1887242.